TOKYO, Japan, May 21, 2026 / Biotech Newswire / -- United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineering of disease-associated macrophages and dendritic cells, today announced the acquisition of multiple assets from Carisma Therapeutics Inc..
United Immunity plans to leverage these innovative assets in combination with its PEG-free, pullulan-coated lipid nanoparticle (P-LNP) delivery system to generate in vivo CAR-M and other genetically engineered macrophages. This integrated approach aims to advance next-generation therapies for solid tumors and fibrosis diseases.
“Both assets has novel technologies to boost the efficacy of in vivo engineered anti-tumor or anti-fibrotic macrophages,” said Masato Kishida, Chief Executive Officer of United Immunity. “Our in vivo CAR-M therapy boosted by these proprietary assets represent a promising therapeutic approach for patients with solid tumors. In addition, United Immunity’s active targeting in vivo CAR-M strategy may provide an improved safety profile by reducing the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are frequently associated with CAR-T cell therapies.”
Semantic keywords: Acquisition; macrophage assets; United Immunity; Carisma Therapeutics; Fibrosis; Neoplasms; Lipid Nanoparticles; cancer; liver fibrosis; Myeloid Targeting Platform; in vivo engineering; disease-associated macrophages; dendritic cells; pullulan-coated lipid nanoparticle; P-LNP delivery system; in vivo CAR-M; genetically engineered macrophages; solid tumors; fibrosis diseases; anti-tumor macrophages; anti-fibrotic macrophages; cytokine release syndrome; CRS; immune effector cell-associated neurotoxicity syndrome; ICANS; CAR-T cell therapies
About United Immunity, Co., Ltd.
Unite the power of immunity and nanoparticle, change the future of patients
United Immunity is a clinical stage biotechnology company developing a novel Myeloid Targeting Platform™ designed to deliver therapeutic payloads directly to disease-associated macrophages and dendritic cells. Its platform combines pullulan nanoparticles (PNPs) and PEG-free, pullulan-coated lipid nanoparticles (P-LNPs) to enable targeted delivery of a wide range of therapeutics, including small molecules, nucleic acids, peptides, and proteins. This approach aims to address major unmet needs across cancer, fibrosis, infectious, autoimmune, and inflammatory diseases.
The company’s lead program, UI-102, leverages its PNP technology to deliver a TLR7/8 small-molecule agonist to tumor-associated macrophages, with the goal of converting immunologically “cold” tumors into “hot,” immune-sensitive ones. In parallel, United Immunity is advancing its P-LNP platform to enable the in vivo generation of CAR-macrophages, opening new therapeutic possibilities for cancer, fibrosis, and autoimmune diseases.
For more information, please visit www.unitedimmunity.co.jp/eng/
www.linkedin.com/company/unitedimmunitycoltd
Contact
United Immunity
Masato Kishida, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Biotech Newswire